Tag: alirocumab

Alirocumab receives EC approval in established atherosclerotic cardiovascular disease

The European Commission (EC) has approved the use of alirocumab (Praluent, Sanofi), a PCSK9 inhibito...

ADVERTORIAL: Taking control of LDL-C when statin therapy is not enough

This content is for distribution within the UK only. This content is for distribution wit...

ACC 2018: Alirocumab reduces cardiovascular events in high-risk patients

The ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who recei...